Reversal of retinal vascular changes associated with ocular neovascularization by small molecules: Progress toward identifying molecular targets for therapeutic intervention

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 75-95

  DeNiro, Michael ^a,b   Al Mohanna, Futwan ^b  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Antiangiogenic drugs; HIF 1; Neovascularization; Reversal; Small molecules; YC 1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 2 [1 ALKYL 5 [(PYRIDIN 2 YLAMINO)METHYL]PYRROLIDIN 3 YLOXY] (ACETYLAMINO) 2 (ALKYLAMINO)PROPIONIC ACID; 3 [5 METHYL 2 (2 OXO 1,2 DIHYDRO INDOL 3 YLIDENEMETHYL) 1H PYRROL 3 YL]PROPRIONIC ACID; 5 [7 (BENZYLOXY) QUINAZOLIN 4 YL]AMINO 4 FLUORO 2 METHYLPHENOL; 5 AMINO 2 NAPHTHALENESULFONATE; AFLIBERCEPT; AG 013711; AG 013764; AG 013958; AGN 211745; ANGIOGENESIS INHIBITOR; AXITINIB; BETA HYDROXYPROPYL CYCLODEXTRIN; BEVACIZUMAB; BEVASIRANIB; COMBRETASTATIN A4; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; JNJ 17029259; JSM 6427; LOSARTAN; PEGAPTANIB; RANIBIZUMAB; RTP 801I; SMALL INTERFERING RNA; SORAFENIB; SU 10944; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; WORTMANNIN; ZM 323881;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CHOROID DISEASE; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GLIOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LASER COAGULATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINOPATHY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

EID: 80455125731     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010075     Document Type: Article

References (147)

1. Russ PK, Gaylord GM, Haselton FR. Retinal vascular permeability determined by dual-tracer fluorescence angiography. Ann Biomed Eng 2001; 29: 638-47.
2. Barinaga M. Shedding light on blindness. Science 1995; 267: 452-3.
3. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 2000; 3: 380-8.
4. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000; 184: 301-10.
5. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28: 488-94.
6. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995; 44: 98-10.
7. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1519-20.
9. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-61.
10. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84: 4226-33.
11. DeNiro M, Alsmadi O, Al-Halafi A, Al-Mohanna F. Pleiotropic Effects of YC-1 Attenuates Pathological Retinal Neovascularization. Invest Ophthalmol Vis Sci 2009a; E-Abstract #41.
12. DeNiro M, Alsmadi O, Al-Mohanna F. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. Exp Eye Res 2009b; (89): 700-17.
13. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-11.
14. DeNiro M, Al-Mohanna FH, Alsmadi O, and Al-Mohanna FA. pleiotropic effects of YC-1 selectively inhibits pathological retinal neovascularization and promotes physiological revascularization in a mouse model of oxygen-induced retinopathy. Mol Pharmacol 2010; 77: 348-67.
15. Michaelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137-80.
16. Wang Y, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VGEF antibody in vitro. Angiogenesis 2004; 7: 335-45.
17. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-16.
18. Presta LG, O'Connor SJ. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
19. Van Wijngaarden P, Williams K. Inhibitors of ocular neovascularization promises and potential problems. JAMA 2005; 293: 1509-13.
20. Warren RS, Matli, MR. Regulation by VEGF of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
21. Gordon MS, Talpaz M. Phase I safety and pharmacokinetic study of recombinant human anti-VEGF in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
22. Friedlander SM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 2006; 124: 13-65.
23. Rosenfeld PJ. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg 2005; 36: 331-5.
24. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
25. Mordenti J, Ferrara N. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27: 536-44.
26. Haritoglou C, Kook D. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
27. Jorge R. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26: 1006-13.
28. Michels S, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035-47.
29. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment endothelium and localization of vascular endothelial growth factor receptor on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421- 8.
30. Peters S, Heiduschka P, Julian S, et al. Tubingen Bevacizumab Study Group. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002.
31. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-72.
32. Ishida S, Usui T, Yamashiro K, et al. VEGF 165-mediated information is required for pathological but not physiological ischaemia-induced retinal neovascularization. J Exp Med 2003; 198: 483-489.
33. Cunningham ET Jr, Adamis AP, Altaweel M, et al; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
34. Nguyen QD, Shah SM, Haller JA, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-9.
35. Gaudrealt J, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46: 726-33.
36. Krohne TU, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146: 508-12.
37. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap (aflibercept) in patient with advanced solid tumors. J Clin Oncol 2010; 28: 207-14.
38. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8: 23-36.
39. Hadj-Slimane R, Lepelletier Y, Lopez N, Garbay C, Raynaud F. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Biochimie 2007; 89: 1234-44.
40. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-16.
41. Cashman SM, Bowman L, Christofferson J, Kumar-Singh R. Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci 2006; 47: 3496-504.
42. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-7.
43. Xia XB, Xiong SQ, Song WT, Luo J, Wang YK, Zhou RR. Inhibition of retinal neovascularization by siRNA targeting VEGF (165). Mol Vis 2008; 14: 1965-73.
44. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 1: 132-8.
45. Motzer RJ, Redman BG, Hudes GR, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
46. Nakahara T, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006; 66: 1434-45.
47. Kelly RJ, Rixe O. Axitinib (AG-013736). Recent Results Cancer Res 2010; 184: 33-44.
48. Rewolinski DA, Grove CG, Cartwright CA, et al. Analysis of angiogenic growth factors in rat retina following inhibition of VEGF-receptor 2. Invest Ophthalmol Vis Sci 2001; 42: S92-S92.
49. Kinose F, Lamartina S, Anderson KD, et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol Vis 2005; 11: 366-73.
50. Jo N, Ju M, Cheung E, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006; 168: 2036-53.
51. Hoyng CB, Vingerling JR, Hooymans JM M, et al. AG-013958 (VEGFR inhibitor) achieves effective choroidal concentrations with minimal systemic effects in cynomolgus monkeys and humans with age-related macular disease. Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 2365.
52. Wang FE, Niesman MR, Rewolinski DA, Miller SS. Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye. Exp Eye Res 2007; 84: 922-33.
53. Patel N, Moshinsky D, Chen H, et al. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther 2003; 306: 838-45.
54. Mendel DB, Xin X, Louie SG, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
55. Cao R, Jensen LDE, Söll I, Hauptmann G, Cao Y. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One 2008; 3: e2748.
56. Whittles CE, Pocock TM, Wedge SR, et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 2002; 6: 513-22.
57. Endo A, Masuda M, Ohmori T, Mochizuki N. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J Recept Signal Transduct Res 2003; 23: 239-54.
58. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 393-402.
59. Singh N, Rashid S, Ambati J, Kontos CD, Higgins E; Ambati BK. Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun 2005; 332: 194-9.
60. Alvarez Y, Jensen L, Reynolds AL, et al. Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PLoS One 2009; 4: e7867.
61. Nowak DG, Woolard J, Amin EM, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008; 20: 3487-95.
62. Hua J, Spee C, Baron E, et al. Therapeutic Potential of Small Molecule Splicing Factor-inhibitor Srpin340 in Treatment of Choroidal Neovascularization (CNV). Invest Ophthalmol Vis Sci 2009; E-2333.
63. Emanuel S, Fuentes-Pesquera A, Connolly PJ, et al. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agent's paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 2004; 66: 635-47.
64. Emanuel S, Susan Hazel, Fuentes-Pesquera A, et al. Inhibition of angiogenesis and retinal neovascularization by an orally available vascular endothelial growth factor receptor inhibitor. Proc Amer Assoc Cancer Res 2005; 46: Abstract #3863.
65. Wang YH, Wang XR, Ni JS, Xin Y, Shi B, Wu JX. Effect of wortmannin on endothelial cell proliferation and migration induced by high glucose Müller cell conditioned medium. Zhonghua Bing Li Xue Za Zhi 2005; 34: 229-32.
66. Kroll J, Kern K, Dietz CT, et al. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart Circ Physiol 2009; 296: H893-H899.
67. Tura A, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S. Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci 2009; 50: 452-61.
68. Ozaki H, Ozaki K, Yamada H, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156: 697-707.
69. Maier P, Junker B, Martin G, Drevs J, Hansen LL, Agostini HT. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005; 243: 593-600.
70. Scheppke L, Aguilar E, Gariano RF, et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 2008; 6: 2337-46.
71. Noronha G, Boccia A, Brodhag T, et al. Discovery of [7-(2, 6-dichlorophenyl)-5-methylbenzo [1, 2, 4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. Med Chem Lett 2007; 17: 602-8.
72. Fabbro D, Ruetz, S, Bodis, S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Des 2000; 15:17-28.
73. Saishin Y, Takahashi K, Seo MS, Melia M, Campochiaro PA. The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Invest Ophthalmol Vis Sci 2003; 44: 3656-62.
74. Kernt M, Neubauer AS, Liegl RG, et al. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. Br J Ophthalmol 2010; 11: 1533-9.
75. Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009; 4: 494-9.
76. Hudson CC, Chiang GG, Otterness DM, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-14.
77. Dutcher JP. Mammalian target of rapamycin (mTOR) Inhibitors. Curr Oncol Rep 2004; 2: 111-5.
78. Dejneka NS, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004; 10: 964-72.
79. Kwon YS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005; (46): 454-60.
80. Nussenblatt RB, Byrnes G, Sen N, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010; 10: 1579-87.
81. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11(7): 355-60.
82. Sausville EA. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001; 7: 2155-8.
83. Kociok N, Poulaki V, Joussen A. Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prematurity. Graefe's Arch Clin Exp Ophthalmol 2007; 245: 258-66.
84. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. Cell cycle inhibition by the anti-angiogenic agent UTNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA 2000; 12: 6427-32.
85. Castronovo V, Belotti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer 1996; 32A: 2520-7.
86. Yasukawa T, Tabata Y, Miyamoto H, Honda Y, Ikada Y, Ogura Y. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci 1999; 40: 2690-6.
87. Falkenstein IA, Cheng L, Wong-Staal F, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res 2008; 7: 599-609.
88. Fernandez-Tornero C, Redondo-Horcajo M, Gomez AM, et al. Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. J Biol Chem 2003; 278: 21774-81.
89. Lange C, Martin G, Konzok K, Moscoso Del Prado J, Hansen LL, Agostini HT. Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res 2007; 85: 323-7.
90. Afzal A, Palii SS, Jurczyk S, et al. Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Res Bull 2010; 81: 320-6.
91. Xin X, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274: 9116-21.
92. Murata T, Hata Y, Ishibashi T, et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 2001; 119: 709-17.
93. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 8: 3650-5.
94. Nandrot EF, Sircar M, Finnemann SC. Novel role for alphavbeta5-integrin in retinal adhesion and its diurnal peak. Am J Physiol Cell Physiol 2006; 290: C1256-C62.
95. Nandrot EF, Finnemann SC. Alphavbeta5-integrin receptors at the apical surface of the RPE: one receptor, two functions. Adv Exp Med Biol 2008; 613: 369-75.
96. Thumann G, Hoffmann S, Hinton DR. Cell biology of the retinal pigmented epithelium. In: Ryan SJ, Ed. Retina. St. Louis, MO: Mosby; 2005: pp. 137-52.
97. Charteris DG, Aylward GW, Sethi C, Luthert P. Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 2007; 245: 93-100.
98. Hiscott P, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res 1999; 18: 167-90.
99. Stragies R, Zischinsky G. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. J Med Chem 2007; 50: 3786-94.
100. Zahn G, Stragies R. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol 2009; 127: 1329-35.
101. Umeda N, Akiyama H. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol 2006; 69: 1820-8.
102. Capone Jr. A, Gonzalez VH, Heier JS, et al. A Phase I Open-Label Study of Single and Repeated Doses of Intravitreal JSM6427, a Small Molecule Integrin 5(31 Antagonist, in Neovascular Age-Related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci 2009; ARVO E-Abstract #1259.
103. Berka JL, Wang DZM, DiNicolantonio R, Alcorn D, Campbell DJ, Skinner SL. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 1995; 36: 1450-8.
104. Danser AHJ, Admiraal PJJ, Deinum J, Dejong P, Schalekamp M. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18.
105. Le Noble FA, Van Straaten HW, Slaaf DW, Stryker Boudier HA. Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick embryo. Eur J Pharmacol 1991; 195: 305-6.
106. De Gasparo M, Inagami T, Wright JW, Unger T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
107. Tamarat R, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation-related pathways. Lab Invest 2002; 82: 747-56.
108. Moravski CJ, Cooper ME. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-104.
109. Lonchampt M, Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest Ophthalmol Vis Sci 2001; 42: 429-32.
110. Otani A, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-28.
111. Nagai N, Urano T, Kubota Y, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005; 46: 1078-84.
112. Tadesse M, Yan Y, Yossuck P, Higgins RD. Captopril improves retinal neovascularization via endothelin-1. Invest. Ophthalmol Vis Sci 2001; 42: 1867-72.
113. Okamura A, Ohishi M. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537-45.
114. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
115. Funatsu H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002; 86: 311-5.
116. Nakamura H, Ohyama T, Inoue T, Arakawa N, Domon Y, Yokoyama T. Role of angiotensin II type 1 receptor on retinal vascular leakage in a rat oxygen-induced retinopathy model. Ophthalmic Res 2009; 41: 210-5.
117. Davies RO, Gomez HJ, Irvin JD, Walker JF. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 (Suppl 2): 215S-229S.
118. Bicket D. Using ACE inhibitors appropriately. Am Fam Phys 2003; 66: 461-8.
119. Kitambi SS, Peterson RT, Malicki JJ. Small molecule screen for compounds that affect vascular development in the zebrafish retina. Mech Dev 2009; 126: 464-77.
120. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 1: 40-51.
121. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
122. Sarlos S, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003; 163: 879-87.
123. Gilbert RE, Berka JL, Kelly DJ, et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78: 1017-27.
124. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.
125. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo controlled trial. Lancet 2008; 372: 1385-93.
126. Alzaid AA, Dinneen SF, Melton LJ 3rd, Rizza RA. The role of growth hormone in the development of diabetic retinopathy. Diabetes Care 1994; 17: 531-4.
127. Kohner EM. Diabetic retinopathy. Metabolism 1975; 24: 1085-102.
128. Merimee T. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N Engl J Med 1978; 298: 1217-22.
129. Hansen R, Malozowski S. Full remission of growth-hormone (GH)-induced retinopathy after GH treatment discontinuation: long-term follow-up. J Clin Endocrinol Metab 2000; 85: 26-7.
130. Smith LE, Chen W, Knapp J, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-9.
131. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001; 108: 2266-72.
132. Higgins RD, Schrier BK. Somatostatin analogs inhibit neonatalretinal neovascularization. Exp Eye Res 2002; 74: 553-9.
133. Wilkinson-Berka JL, Jaworski K, Ninkovic S, Tachas G, Wraight CJ. An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model ofretinopathy. Mol Vis 2007; 13: 1529-38.
134. Nussenblatt RB, Whitcup SM, de Smet MD, et al. Intraocularinflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci 1996; 778: 325-37.
135. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008; 53: 139-49.
136. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008; 6: 622-47.
137. Martidis A, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2000; 119: 1380-3.
138. Degenring RF. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 2003; 87: 361.
139. Jonas JB, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2003; 13: 468-73.
140. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005; 80: 249-58.
141. Kogure A, Kogure S, Yamaguchi T, Kishi S. Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema. Jpn J Ophthalmol 2008; 52: 122-6.
142. Gillies MC, Simpson JM, Larson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-8.
143. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-9.
144. Sherif Z. Corticosteroids in Ophthalmology: past, present and future. Ophthalmologica 2002; 216: 305-15.
145. Kersey JP. Corticosteroid-induced glaucoma: a review of the literature. Eye 2006; 20: 407-16.
146. Wordinger RJ. Effects of glucocorticoids on the trabecular meshwork: Towards a better understanding of glaucoma. Prog Retin Eye Res 1999; 18: 629-67.
147. Otani A, Slike BM, Dorrell MI, et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci USA 2002; 1: 178-83.